DMAC

Business Context and Reporting Period

Company: DiaMedica Therapeutics Inc. (DMAC)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: DiaMedica is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1 (KLK1), for the treatment of preeclampsia (PE) and acute ischemic stroke (AIS). The company has no commercial product revenue and relies on equity financing and interest income.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose to $16.2 million for the six months ended June 30, 2025, compared to $11.4 million in the prior year period.
  • R&D Expenses: Increased to $11.5 million (from $7.6 million) due to the continuation and global expansion of the ReMEDy2 clinical trial for AIS and increased manufacturing development.
  • G&A Expenses: Increased to $4.7 million (from $3.8 million), driven primarily by higher share-based compensation and personnel costs, partially offset by reduced legal fees.
• Reduced Interest Income: Other income, net, decreased to $0.8 million (from $1.1 million) due to lower average balances of marketable securities.
• Shareholder Equity: Total shareholders' equity decreased to $27.2 million from $40.7 million at year-end 2024, reflecting the net loss and unrealized losses on securities.

Outlook, Risks, and Management Commentary

Clinical Progress

• Preeclampsia (PE): Interim results from Part 1a of the Phase 2 study (released July 2025) showed DM199 was safe, well-tolerated, and demonstrated rapid, statistically significant blood pressure reductions with no placental transfer. The company plans to submit an Investigational New Drug (IND) application in the U.S. in the second half of 2025.
• Acute Ischemic Stroke (AIS): The Phase 2/3 ReMEDy2 trial is experiencing slower-than-expected site activations and enrollment. Management attributes this to staffing shortages, protocol logistics, and competition for subjects. Mitigation strategies include expanding the internal clinical team and bringing trial activities in-house.

Liquidity and Capital Resources

• Subsequent Financing: In July 2025, the company completed a private placement raising net proceeds of approximately $29.9 million.
• Runway: Management expects current cash resources, including the July 2025 proceeds, to fund operations for at least the next 12 months.
• Future Needs: The company anticipates needing substantial additional capital to complete clinical trials and regulatory activities. Future funding requirements depend on trial enrollment rates and expansion plans.

Risks and Contingencies

• Legal Proceedings: The company discontinued its pursuit of a legal matter against ICON/PRA Netherlands regarding withheld clinical data after a court ruling found no default under the agreement.
• Regulatory Risks: Potential delays in FDA review due to government funding and staffing changes.
• Development Risks: Failure to replicate interim PE data in future trials or inability to resolve enrollment issues in the ReMEDy2 trial could delay or prevent regulatory approval.

Key Facts for Investor Verification

• Enrollment Rates: Verify the actual progress of site activations and patient enrollment in the ReMEDy2 trial against management's mitigation efforts.
• PE Trial Next Steps: Confirm the timeline for the submission of the U.S. IND application and the initiation of Part 1b of the PE study.
• Cash Burn Rate: Monitor quarterly cash usage to ensure the 12-month runway remains accurate given the increased operating expenses.
• Financing Terms: Review the terms of the July 2025 private placement for any dilutive effects or restrictive covenants.
• Regulatory Environment: Assess potential impacts of FDA staffing changes on the review timeline for the upcoming IND application.